UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from ________ to________ Commission File Number: 1-8351 CHEMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati ...

Financial Data and Key Metrics Changes - VITAS' net revenue for Q4 2021 was $316 million, a decline of 4.8% compared to the prior year, primarily due to a 4.2% decrease in days of care [22] - Roto-Rooter generated quarterly revenue of $225 million in Q4 2021, an increase of $23.8 million or 11.8% compared to the prior year [26] - VITAS' gross margin, excluding Medicare cap and pandemic-related costs, was 28.5%, a decline of 109 basis points from Q4 2020 [24] - Roto-Rooter's gross margin, excluding COVID impact, was 52.7%, a 77 basis point increase from Q4 2020 [29] Business Line Data and Key Metrics Changes - VITAS experienced a decline in average daily census by 4.2% year-over-year, with total admissions down 9.5% compared to Q4 2020 [36] - Roto-Rooter's residential revenue increased by 11.2% to $152 million, with growth across all service segments [26][27] - Roto-Rooter's commercial revenue totaled $53.9 million, an increase of 14.8% over the prior year [28] Market Data and Key Metrics Changes - The nursing home-based patient ratio in VITAS' average daily census stabilized at 15.6% in Q3 and Q4 2021, up from a low of 14.3% in Q1 2021 [14] - VITAS anticipates a slow improvement in senior housing admissions in the first half of 2022, with acceleration expected in the second half [14] Company Strategy and Development Direction - The company is focusing on hiring and retention initiatives to address labor shortages in the healthcare sector, particularly for VITAS [9][10] - Roto-Rooter plans to continue passing through price increases to maintain technician compensation and expand its workforce [16][62] - The company is open to potential acquisitions of well-positioned hospices due to the changing landscape and lower multiples in the market [50][82] Management's Comments on Operating Environment and Future Outlook - Management noted that the healthcare labor market remains challenging, with staffing shortages impacting VITAS' ability to respond to referrals [9][42] - The company expects inflationary pressures to continue affecting margins until reimbursement rates catch up, which is anticipated to occur with the October 2022 adjustments [11][73] - Management expressed confidence in the long-term growth of the hospice industry, expecting a return to pre-pandemic levels of admissions and revenue growth [88] Other Important Information - Chemed repurchased 495,529 shares for $246 million during the quarter, with approximately $202 million remaining under the share repurchase authorization [32] - The full-year 2022 earnings guidance for VITAS anticipates a revenue decline of 1.5% to 2.5% compared to 2021, while Roto-Rooter is expected to achieve revenue growth of 8% to 9.5% [33][34] Q&A Session Summary Question: Discussion on VITAS admission decline and labor shortages - Management clarified that the decline is not solely a demand issue but also due to healthcare system disruptions and staffing shortages [42][43] Question: Clarification on recruiting and retention metrics - Management stated they do not release specific metrics but emphasized improvements in recruiting performance compared to peers [45][52] Question: Impact of inflation on labor costs and guidance - Management acknowledged that inflationary pressures are built into their guidance, with expectations for continued investment in clinical staff [55][57] Question: Roto-Rooter pricing increases and demand - Management confirmed mid- to high single-digit price increases were implemented, with further increases anticipated throughout 2022 [62][64] Question: Expectations for senior housing referrals and median length of stay - Management expects normalization of senior housing referrals and median length of stay by the end of 2022 [101]

45202 (Zipcode) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2021 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 1-8351 CHEMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 31-0791746 (State or other jurisdiction of incorporation or org ...

Chemed Corporation (NYSE:CHE) Q3 2021 Earnings Conference Call October 29, 2021 10:00 AM ET Company Participants Sherri Warner - IR Kevin McNamara - President and CEO Dave Williams - EVP and CFO Nick Westfall - President and CEO-Chemed's VITAS Healthcare Corporation Subsidiary Conference Call Participants Joanna Gajuk - Bank of America Frank Morgan - RBC Capital Operator Good day, ladies and gentlemen. Thank you for standing by and welcome to Chemed Corporation Third Quarter 2021 Earnings Conference Call. A ...

| --- | --- | |-------|------------------------------| | | | | (IRS | Employer Identification No.) | | | 45202 (Zip code) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2021 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 1-8351 CHEMED CORPORATION (Exact name of registran ...

Chemed Corporation (NYSE:CHE) Q2 2021 Earnings Conference Call July 28, 2021 10:00 AM ET Company Participants Sherri Warner - Investor Relations Kevin McNamara - President & Chief Executive Officer Dave Williams - Executive Vice President & Chief Financial Officer Nick Westfall - President and Chief Executive Officer-Chemed's VITAS Healthcare Corporation subsidiary Conference Call Participants Frank Morgan - RBC Capital Markets Joanna Gajuk - Bank of America Operator Good day, and thank you for standing by. ...

| --- | --- | --- | --- | |-------|------------------------------|-------|-------| | | | | | | | | | | | | CHEMED CORPORA | | Z | | | | | | | | | | | | | Results as of March 31, 2021 | | | | | | | B | | | He | | are | Safe Harbor and Regulation G Statement This presentation contains information about Chemed's EBITDA, Adjusted EBITDA, EBIT, Adjusted EBIT, Adjusted Net Income and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to und ...

| --- | --- | |-------|------------------------------------| | | | | (IRS | Employer Identification No.) 45202 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2021 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 1-8351 CHEMED CORPORATION (Exact name of registrant as speci ...

Chemed Corporation (NYSE:CHE) Q1 2021 Earnings Conference Call March 28, 2021 10:30 AM ET Company Participants Sherri Warner – Investor Relations Kevin McNamara – President and Chief Executive Officer Dave Williams – Executive Vice President and Chief Financial Officer Nick Westfall – President and Chief Executive Officer-Chemed's VITAS Healthcare Corporation subsidiary Conference Call Participants Joanna Gajuk – Bank of America Frank Morgan – RBC Capital Markets Operator Good morning. Thank you for standin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from ________ to________ Commission File Number: 1-8351 CHEMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati ...